Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...
APEIRON Biologics AG today announced it would present data on two of its key programs in three poster presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held on June 1-5, 2018, in Chicago, IL. Presseaussendung Press Release
APEIRON Biologics AG and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. Press release Presseaussendung
APEIRON Biologics AG today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing. Press release Presseaussendung